Outcomes of early‐treated infants with spinal muscular atrophy: A multicenter, retrospective cohort study

Natalie L. Goedeker,Amanda Rogers,Mark Fisher,Kapil Arya,John F. Brandsema,Hiba Farah,Michelle A. Farrar,Marcia V. Felker,Melissa Gibbons,Omer Abdul Hamid,Matthew Harmelink,Karen Herbert,Elizabeth Kichula,Kiana King,Arpita Lakhotia,Bo Hoon Lee,Nancy L. Kuntz,Julie Parsons,Rebecca Rehborg,Aravindhan Veerapaniyan,Craig M. Zaidman
DOI: https://doi.org/10.1002/mus.28267
2024-10-08
Muscle & Nerve
Abstract:Introduction/Aims While prompt identification and treatment of infants with spinal muscular atrophy (SMA) can ameliorate outcomes, variability persists. This study assessed management and outcomes of early‐treated infants with SMA. Methods We analyzed retrospective data at 12 centers on infants with SMA treated at age ≤6 weeks from August 2018 to December 2023. Results Sixty‐six patients, 35 with two SMN2 copies and 31 with ≥3 SMN2 copies, were included. Twenty‐five (38%, 22 with two SMN2 copies), had SMA findings before initial treatment which was onasemnogene abeparvovec in 47 (71%) and nusinersen in 19 (29%). Thirty‐two received sequential or combination treatments, including 16 adding nusinersen or risdiplam due to SMA findings following onasemnogene abeparvovec. All sat independently. Compared to children with ≥3 SMN2 copies, those with two SMN2 copies were less likely to walk (23/34 [68%] vs. 31/31 [100%], p
neurosciences,clinical neurology
What problem does this paper attempt to address?